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Type one diabetes (T1D: (juvenile onset) whilst being a
chronic disease, the defining feature of which is the
destruction of the insulin-secreting beta-cells and subse-
quent dependence on exogenous insulin, is possessing
with hallmark characteristics of the complex T cell-
mediated autoimmunity superimposed on genetic sus-
ceptibility. Both genetic and environmental factors com-
bine to precipitate disease, and the outcome of the
pathological process is dependent on multiple interre-
lated factors. The annual global incidence of T1D is
increasing by 3-5% per year.
Both HLA-genes and immune markers (autoantibo-
dies/autoAbs) have been validated as predictive biomar-
kers of the subsequent development of the disease in
higher-risk relatives and the lower-risk general popula-
tion. Over the last three decades, using a combination
of genomic, proteomic, and metabolomic biomarkers,
clinicians are now able to quantify an individual’s dis-
ease risk from 1 in 100,000 to more than 1 in 2. The
HLA genes are reported to account for approximately
40-50% of the familial aggregation of T1D.
Current approaches for the prediction of T1D in
screening studies take advantage of genotyping HLA-DR
and HLA-DQ loci, which is then combined with family
history and screening for autoAbs directed against islet-
cell Ags. Inclusion of additional moderate HLA risk
haplotypes may help identify the majority of children
withT1D before the onset of the disease. Fine mapping
and functional studies are gradually revealing the com-
plex mechanisms whereby immune self-tolerance is lost,
involving adaptive immunity. Genetic prediction of T1D
risks is showing promise of use for preventive strategies.
And understanding of the genetics, environmental fac-
tors, and natural history of T1D has resulted in greater
understanding of the etiology and epidemiology of the
disease.
The clinical care of patients with T1D has greatly
improved over the past few decades; however, it remains
impossible to completely normalize blood sugar utilizing
currently available tools. Meanwhile, subclinical and pre-
dictive diagnostic armamentarium is still far from being
unique, and innovative algorithms that significantly dif-
fer from the clinical approaches should become the
major bricks to be laid into the basis of a subclinical
diagnosis of pre-T1D.
Generally, there are three levels desirable for an opti-
mal pre-T1D and T1D-related healthcare, namely,
(i) 1st level: prediction of the familial predisposition,
targeted prevention of pre-T1D early in childhood;
(ii) 2nd level: prediction of early/premature aging and
targeted prevention of T1D-related pre-stages;
(iii) 3rd level: prediction of secondary complications in
the cohort of T1D-patients and creation of personalized
treatment modes tailored to the patient to prevent post-
T1D complications frequently developed.
Accurate prediction is vital for T1D prevention so that
preventive treatment can be given to those individuals
who are most likely to develop the disease. Predictive
medicine is intended more so for healthy individuals, its
purpose being to determine whether susceptibility to a
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particular disease is increased or not. And the long
asymptomatic period before the onset of clinical T1D
offers good opportunities for disease prevention. And
preventive portion of PPPM (or preventive care) refers
to measures taken to prevent diseases rather than curing
them or treating their symptoms. Indeed, many chronic
diseases like T1D may be preventable by avoiding those
factors that trigger the disease process (primary preven-
tion) or by use of treatment modes that modulate the
disease process before the onset of clinical symptoms
(secondary prevention).
The utility of predictive biomarkers to monitor T1D-
related stages and to predict the transitions is dependent
on three key parameters, which must be carefully
assessed: sensitivity, specificity and positive predictive
value. Recent advances in genomics, proteomics, and
bioinformatics offer a great opportunity for biomarker
discovery, and the newly identified biomarkers and bio-
predictors have the potential to bring increased accuracy
in T1D diagnosis and classification, as well as persona-
lized therapeutic monitoring. The latter including effica-
cious quenching of autoimmune insulitis (pre-T1D) and
prevention of clinical T1D will require detection of the
earliest events in the process. But currently, there is no
effective treatment strategy to restore glucose regulation
in T1D patients. So, personalized medicine is a medical
model that proposes the customization of healthcare,
with all decisions and practices being tailored to the indivi-
dual T1D patient by use of genetic or other information.
So far, antiislet autoAbs are most widely used as
serum biomarker in making and verifying the diagnosis
of subclinical and clinical stages of T1D, but T-cell
readouts and metabolome studies might strengthen and
bring forward diagnosis. The autoAbs can be detected
before (as early as 5-10 years before the clinical onset)
and at time of clinical diagnosis of disease and could
thus be used to predict risks of developing T1D in first
degree relatives of probands.
Monotherapy for T1D has not resulted in sustained
tolerance and preservation of C-peptide production;
individuals still progress to a complete loss of endogen-
ous insulin producing ability. Combination therapy is
likely to be necessary as different pathways and arms of
the immune system can be targeted. However, current
preventive clinical trials mostly focus on environmental
triggers. At the same time, there is an immediate need
to restore both beta-cell function and immune tolerance
to control disease progression and ultimately cure T1D,
and so, the strategy of prevention of pre-T1D-T1D tran-
sition should contain two critical points, i.e., (i) obliga-
tory arrest/blockage of autoagression and (ii) restoration
of beta-cell infrastructure and function. As it is evident,
strategies for disease intervention, therefore, will not
only require the induction of T-cell tolerance by tipping
the balance towards regulation but will also need to
contain approaches that result in the scavenging of
inflammatory mediators, in order to facilitate repair.
For instance, efficiently halting immune attack in the
islet milieu by an effector-specific manner apparently
provides the preventive and therapeutic strategies in
T1D. For instance, FoxP3-expressing CD4+ Tregs are
potential candidates to control autoimmunity because
they play a central role in maintaining self-tolerance.
Preservation and/or restoration of structural architec-
tonics and function of beta cells can be accomplished by
the use of (i) immune, cell-based and/or gene therapy
(e.g., islet transplantation could be an appropriate treat-
ment to accomplish insulin independence and long-term
homeostasis of glucose in T1D), and (ii) regenerative
drug-based treatment including stem cell (SC) technolo-
gies. Tremendous progress has been made in the field of
islet regeneration in the past few years, and beta-cell
replacement by islet transplantation and/or SCs has pro-
vided new hope for a cure of T1D.
However, it is difficult to protect the islet grafts or
beta-cells restored from subsequent immune attack and
prolong their survival. The optimal therapeutic approach
for T1D in this connection should ideally preserve the
remaining b-cells, restore b-cell function, and protect
the replaced insulin-producing cells from autoimmunity.
SCs possess unique immune and restorative properties
that could be harnessed to improve the treatment of
T1D; indeed, SCs may re-establish peripheral tolerance
toward b-cells through reshaping of the immune
response and inhibition of autoreactive CTCs.
Along with combination therapy, we believe targeted
and specific immune therapies are needed to prevent
and ultimately cure T1D. Those therapies can be
designed to specifically target insulin-HLA complexes
and the TCRs that recognize them. Small molecule
approaches can block autoAg presentation or TCR
recognition of autoAg-HLA complexes. Another strategy
includes designing MAbs to recognize autoAg peptide-
HLA complexes with the peptide in a defined register
recognized by the autoreactive TCRs. As the structural
basis of autoAg presentation and T cell recognition
advances, these novel approaches become realistic.
There is thus a requirement for an increased, collabora-
tive effort between clinical endocrinologists, specialists
in PPPM, stem cell biologists and immunologists in
order to tailor an optimal and personalized therapeutic
strategy for the treatment of this debilitating disease.
Moreover, implementation of PPPM program requires
the adjusted technology for adequate interpretation of
diagnostic data before the current model “physician-
patient” could be gradually displaced by a novel model
“medical advisor-healthy men-at-risk”. Systemic
approach to formation of an innovative infrastructure
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regarding prediction and prevention algorithms is an
ultimate approach that will contribute to modernization
of T1D-related healthcare significantly. An understand-
ing and possibly a complete description of the factors
underlying the burden of T1D will provide policy-
makers, healthcare providers and mentors with an
opportunity to guide primary and secondary preventive
initiatives at both individual and community levels. Our
challenge is that new guidelines should create the robust
juristic and economic platform for advanced medical
services utilizing the cost-effective models of risk assess-
ments followed by tailored preventive and personalized
treatments focused on the precursor stages of T1D.
What is a realistic timeline for the incorporation of
PPPM into the practice of endocrinology and T1D, in
particular? Patients and relatives alike want interven-
tions that work right now. And PPPM would thus pro-
mise to sharply reverse the ever escalating costs of T1D-
related diagnosis and treatment to stratify patients and
disease, less expensive approaches to drug discovery,
preventive medicine and wellness. PPPM also promises
to improve T1D patient outcomes, and to empower
both the patient and the physician.
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